Recently, it has been reported that the activated form of mTOR, phospho-mTOR (p-mTOR), detected at nuclear level, was expressed more frequently in triple negative (TN) human breast cancers compared with non-TN cancers[3], suggesting that mTOR may play a more important role in the progression of TNBC and could be considered a new target for the treatment of this tumour sub-type[9,13-15]. Here, MTOR is linked to breast carcinoma.